Quantitation method for colistimethate sodium in pharmaceutical aerosol samples using high performance liquid chromatography (HPLC) Source: International Congress 2016 – Airway biomarkers Year: 2016
Effect of I:E ratio on delivery of colistimethate sodium from breath-enhanced and breath-activated nebulizers Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
In vitro evaluation of the Twincer colistin dry powder inhaler as a non-cough-inducing alternative to Colobreathe Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016
Pharmacokinetics of tobramycin nebulizer solution (300mg/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012
Lung Clearance Index (LCI) and FEV1 on the evaluation of the effect of tobramycin solution for inhalation (TIS) among patients with cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment Year: 2014
Inhaled dry powder mannitol in cystic fibrosis (CF): Microbiology results from the 6 month double-blind CF301 study Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010
Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Study of adherence to the use of inhaled sodium colistimethate through the I-neb® nebulization system Source: International Congress 2014 – Different interesting issues in respiratory infections: 1 Year: 2014
Delivery of dornase alfa via breath-actuated nebulizer: In-vitro measures of performance Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013
Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013
Effect of high dose tobramicin (TOBI®) inhalation on respiratory values in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 503s Year: 2003
Effect of nebulizer system on tobramycin concentration using functional respiratory imaging (FRI) Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016
Effects of dornase alfa and hypertonic saline on gas mixing in lung periphery in children with cystic fibrosis Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects Year: 2014
Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis Source: Eur Respir Rev 2013; 22: 476-486 Year: 2013
Comparison of tobramycin 80 mg (IV-Preparation) and 300 mg solution for inhalation in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005
Airway surface liquid concentrations of aztreonam lysine for inhalation in children with cystic fibrosis: A modeling study Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013
Alternating inhaled antibiotic therapy in CF: A single center analysis Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015
Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Use of an electronic monitoring system to generate objective information on patients’ adherence to taking treatments of a novel inhaled tobramycin solution Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013
In vitro comparison of dose accuracy of two budesonide/formoterol dry powder inhalers Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015